RESULTS OF THE IV PHASE OF THE OPEN CLINICAL TRIAL ON EFFICACY AND SAFETY OF ABATACEPT USAGE IN CHILDREN AND ADOLESCENTS WITH POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS WITHOUT SYSTEMIC MANIFESTATIONS IN RUSSIA

Aim: to assess efficacy and safety of abatacept usage in children and adolescents with polyarticular juvenile idiopathic arthritis without systemic manifestations. Patients and methods: 15 patients aged 13 (11; 14,5) years old were included into the study; the mean duration of disease course was 4 (3; 5) years. The disease was diagnosed based on the ILAR criteria. All the patients were performed routine clinical and laboratory examination. Efficacy of treatment was assessed according to the pediatric criteria for improvement of the American College of Rheumatology (ACR_pedi). Target characteristics of treatment efficacy were: the number of patients with 30/50/70/90% improvement according to the ACR_pedi criteria during first 4 months from the therapy administration, and then – every 2 months; percentage of non-active stage and remission achievement. Results: in 4 months after beginning of treatment improvement according to the ACR_pedi 30/50 criteria was observed in 60/30% of patients; in 6 months according to the ACR_pedi 30/50/70 criteria — in 80/40/40%, respectively; in 12 months according to the ACR_pedi 70 criteria — in 80% of patients. Non-active stage of disease in 6 and 12 months was confirmed in 6/15 (30%) and 10/15 (60%) of patients, respectively. Remission was confirmed in 10/15 (60%) of children in 12 months of therapy. Side effects were observed in 6/15 (40%) of children and were mild. Three patients had relapses of Herpes labialis infection, 3 other had acute respiratory tract infections. Conclusions: abatacept is effective for treatment of polyarticular juvenile idiopathic arthritis, resistant to steroids, methotrexate and combined immunosuppressive treatment.

1. Kahn P. Juvenile idiopathic arthritis: an update for the clinician. Bull. NYU Hospital Joint Dis. 2012; 70 (3): 152–166.

2. Beena J. P. Juvenile idiopathic arthritis: review of the literature and case report. J. Dent. Child (Chic). 2013; 80(1): 25–30.

3. Alexeeva E.I., Alexeeva A.M., Valieva S.I., Bzarova T.M., Denisova R.V., Mikhaleva G.V. Effect of infliximab on functional class dynamics and radiographic alterations of cartilaginous and osseous tissues of joints in patients with different forms of juvenile arthritis. Issues of Modern Pediatrics. 2008; 7(4): 30-44.

4. Ruperto N., Lovell D. J., Li T., Sztajnbok F. Abatacept improves health-related quality of life, pain, sleep quality, and daily participation in subjects with juvenile idiopathic arthritis. Arthr. Care Res. (Hoboken). 2010; 62 (11): 1542–1551.

5. Otten M. H., Anink J., Spronk S., van Suijlekom-Smit L. W. Efficacy of biological agents in juvenile idiopathic arthritis: a systematic review using indirect comparisons. Ann. Rheum. Dis. 2012; 21.

6. Ungar W. J., Costa V., Hancock-Howard R., Feldman B. M., Laxer R. M. Cost-effectiveness of biologics in polyarticular-course juvenile idiopathic arthritis patients unresponsive to diseasemodifying antirheumatic drugs. Arthr. Care Res. (Hoboken). 2011; 63 (1): 111–119.

7. Alexeeva E.I., Valieva S.I., Denisova R.V., Bzarova T.M. Prospects for the use of soluble TNF α receptors in the therapy of juvenile arthrites. Issues of Modern Pediatrics. 2008; 7 (5): 51-56.

8. Horneff G. Update on biologicals for treatment of juvenile idiopathic arthritis. Exp. Opin. Biol. Ther. 2013; 13 (3): 361–376.

9. Beukelman T., Patkar N. M., Saag K. G., Tolleson-Rinehart S., Cron R. Q., DeWitt E. M., Ilowite N. T., Kimura Y., Laxer R. M., Lovell D. J., Martini A., Rabinovich C. E., Ruperto N. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthr. Care Res. (Hoboken). 2011; 63(4): 465–482.

10. Baranov A.A., Alexeeva E.I., Bzarova T.M., Valieva S.I., Denisova R.V. et al. Management protocol for patients with juvenile arthritis. Issues of Modern Pediatrics. 2013; 13(1): 37-56.

11. Lagana B., Vinciguerra M., D'Amelio R. Modulation of T-cell co-stimulation in rheumatoid arthritis: clinical experience with abatacept. Clin Drug Investig. 2009; 29(3): 185–202.

12. Kormendy D., Hoff H., Hoff P., Broker B. M., Burmester G. R., Brunner-Weinzierl M. C. Impact of the CTLA-4/CD28 axis on the processes of joint inflammation in rheumatoid arthritis. Arthritis Rheum. 2013; 65 (1): 81–87.

13. Li X., Zhang C., Zhang J., Zhang Y., Wu Z., Yang L., Xiang Z., Qi Z., Zhang X., Xiao X. Polymorphisms in the CTLA-4 gene and rheumatoid arthritis susceptibility: a meta-analysis. J. Clin. Immunol. 2012; 32 (3): 530–539.

14. Kremer J. M., Dougados M., Emery P. et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005; 52: 2263–2271.

15. Bergman M., Furfaro N. Individualizing therapy for rheumatoid arthritis: New strategies for maximizing treatment outcomes. PCE Updates in Rheumatology. 2010; 3 (2): 1–12.

16. Smolen J., Aletaha D., Bijlsma J. W. J. et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann. Rheum. Dis. 2010; 69: 631–637.

17. Kremer J. M., Russell A. S., Emery P., Abud-Mendoza C., Szechinski J., Westhovens R., Li T., Zhou X., Becker J. C., Aranda R., Peterfy C., Genant H. K. Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial. Ann. Rheum. Dis. 2011; 70(10): 1826–1830.

18. Guyot P., Taylor P. C., Christensen R., Pericleous L., Drost P., Eijgelshoven I., Bergman G., Lebmeier M. Indirect treatment comparison of abatacept with methotrexate versus other biologic agents for active rheumatoid arthritis despite methotrexate therapy in the United Kingdom. J. Rheumatol. 2012; 39(6): 1198–1206.

19. Weinblatt M. E., Schiff M., Valente R., van der Heijde D., Citera G., Zhao C., Maldonado M., Fleischmann R. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study. Arthritis Rheum. 2013; 65(1): 28–38.

20. Westhovens R. The long-term effectiveness and safety of abatacept in rheumatoid arthritis. J. Clin. Rheumatol. Muscu loskeletal Med. 2011; 2(1): 25–28.

21. Conaghan P. G.., Durez P., Alten R. E., Burmester G.-R. Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: the ASSET randomised controlled trial. Ann. Rheum. Dis. 2013; 72: 1287–1294.

22. Kremer J. M., Genant H. K., Moreland L. W., Russell A. S. et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann. Intern. Med. 2006; 144: 865–876.

23. Weinblatt M. E., Moreland L. W., Westhovens R. Safety of abatacept administered intravenously in treatment of rheumatoid arthritis: Integrated analyses of up to 8 years of treatment from the Abatacept clinical trial program. J. Rheumatol. 2013; 40: 6.

24. Schiff M. H., Pritchard C., Huffstutter J. E. et al. The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-TNF therapy or were directly switched to abatacept: the ARRIVE trial. Ann. Rheum. Dis. 2009; doi: 10.1136/ard.2008.099218.

25. Schiff M., Keiserman M., Codding C., Songcharoen S. et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multicentre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann. Rheum. Dis. 2008; 67: 1096–1103.

26. Kremer J. M., Genant H. K., Moreland L. W., Russell A. S. et al. Results of a two–year follow up study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis Rheum. 2008; 58: 953–963.

27. Genant H. K., Peterfy C. G., Westhovens R., Becker J. C. et al. Abatacept inhibits structural damage progression in rheumatoid arthritis: results from the long-term extension of the AIM trial. Ann.Rheum. Dis. 2008; 67: 1084–1089.

28. Westhovens R., Robles M., Ximenes A. D. et al. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann. Rheum. Dis. 2009. Р. 2208–2225.

29. Emery P., Durez P., Dougados M. et al. Efficacy of abatacept in delaying the development of rheumatoid arthritis (RA) in adult patients with undifferentiated inflammatory arthritis at high risk of developing RA. [OP-0130]. Ann. Rheum. Dis. 2008; 67 (Suppl. II): 89.

30. Westhovens R., Kremer J., Moreland L. et al. Durable impact on disease activity and consistent safety through 5 years in abatacepttreated RA patients background methotrexate. [FRI0171]. Ann. Rheum. Dis. 2008; 67 (Suppl. II): 341.

31. Khraishi M., Russell A., Olszynski W. P. Safety profile of abatacept in rheumatoid arthritis: A review. Clin. Ther. 2010; 32 (11): 1855–1870.

32. Bigbee C. L., Gonchoroff D. G., Vratsanos G. et al. Abatacept treatment does not exacerbate chronic Mycobacterium tuberculosis infection in mice. Arthritis Rheum. 2007; 56: 2557–2565.

33. Sibilia J., Westhovens R. Safety of T-cell co-stimulation modulation with abatacept in 4 patients with rheumatoid arthritis. Clin. Exp. Rheumatol. 2007; 25 (Suppl. 46): 46–56.

34. Ruperto N., Lovell D. J., Quartier P., Ruperto N. Efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis & Rheumatism. 2010; 62 (6): 1792–1802.

35. Goldzweig O., Hashkes P. J. Abatacept in the treatment of polyarticular JIA: development, clinical utility, and place in therapy. Drug Des. Dev. Ther. 2011; 5: 61–70.

36. Wallace C. A., Giannini E. H., Huang В., Itert L., Ruperto N. Childhood Arthritis Rheumatology Research Alliance (CARRA), Pediatric Rheumatology Collaborative Study Group (PRCSG) and Paediatric Rheumatology International Trials Organisation (PRINTO), American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. Arthritis Care Res. 2011; 63: 929–936.

37. Bzarova T.M., Alexeeva E.I., Peterkova V.A. Role of disease factors and antirheumatic therapy factors in the development of dwarfism in the children with juvenile rheumatoid arthritis. Issues of Modern Pediatrics. 2006; 5(5): 13-18.